{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:14:15Z","timestamp":1789010055315,"version":"build-2803163510"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T00:00:00Z","timestamp":1660435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21H02846"],"award-info":[{"award-number":["21H02846"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515012512"],"award-info":[{"award-number":["2022A1515012512"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.neuropharm.2022.109219","type":"journal-article","created":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T17:28:00Z","timestamp":1660498080000},"page":"109219","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"special_numbering":"C","title":["Arketamine, a new rapid-acting antidepressant: A historical review and future directions"],"prefix":"10.1016","volume":"218","author":[{"given":"Ji-chun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8892-0439","authenticated-orcid":false,"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.109219_bib1","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.1093\/nar\/gkab258","article-title":"Short DNA\/RNA heteroduplex oligonucleotide interacting proteins are key regulators of target gene silencing","volume":"49","author":"Asada","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuropharm.2022.109219_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature10130","article-title":"NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses","volume":"475","author":"Autry","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109219_bib3","doi-asserted-by":"crossref","first-page":"12547","DOI":"10.1523\/JNEUROSCI.0324-14.2014","article-title":"A positive autoregulatory BDNF feedback loop via C\/EBP\u03b2 mediates hippocampal memory consolidation","volume":"34","author":"Bambah-Mukku","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109219_bib4","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.neubiorev.2017.03.010","article-title":"Ketamine as a rapid-acting agent for suicidal ideation: a meta-analysis","volume":"77","author":"Bartoli","year":"2017","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2022.109219_bib5","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1007\/s00213-021-06049-6","article-title":"Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research","volume":"239","author":"Bender","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109219_bib6","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib7","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/j.1471-4159.2004.02524.x","article-title":"Activation of AP-1 and CRE-dependent gene expression via mu-opioid receptor","volume":"90","author":"Bilecki","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2022.109219_bib8","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1038\/s41380-021-01093-2","article-title":"Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability","volume":"26","author":"Bonaventura","year":"2021","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtn.2022.05.037","article-title":"Suppression of abnormal alpha-synuclein expression by activation of BDNF transcription ameliorates Parkinson's disease-like pathology","volume":"29","author":"Cao","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.neuropharm.2022.109219_bib10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41420-022-01063-9","article-title":"Regulation of BDNF transcription by Nrf2 and MeCP2 ameliorates MPTP-induced neurotoxicity","volume":"8","author":"Cao","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.neuropharm.2022.109219_bib11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172995","article-title":"Recent advances in the antidepressant actions of ketamine and agents having ketamine-like antidepressant profiles","volume":"196","author":"Chaki","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109219_bib13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.brainresbull.2022.02.004","article-title":"Brain-gut-microbiota axis in depression: a historical overview and future directions","volume":"182","author":"Chang","year":"2022","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2022.109219_bib14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pbb.2019.04.008","article-title":"Comparison of antidepressant and side effects in mice after intranasal administration of (R,S)-ketamine, (R)-ketamine, and (S)-ketamine","volume":"181","author":"Chang","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109219_bib15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1176\/appi.ajp.2020.20050653","article-title":"Impact of the KCNQ2\/3 channel opener ezogabine on reward circuit activity and clinical symptoms in depression: results from a randomized controlled trial","volume":"178","author":"Costi","year":"2021","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib16","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1001\/archgenpsychiatry.2010.90","article-title":"A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression","volume":"67","author":"Diazgranados","year":"2010","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib17","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/ALN.0b013e3181ed09a2","article-title":"Taming the ketamine tiger. 1965","volume":"113","author":"Domino","year":"2010","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2022.109219_bib18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/cpt196563279","article-title":"Pharmacologic effects of CI-581, a new dissociative anesthetic, in man","volume":"6","author":"Domino","year":"1965","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2022.109219_bib19","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-2999(97)01116-3","article-title":"Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord","volume":"333","author":"Ebert","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109219_bib20","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1523\/JNEUROSCI.0367-19.2019","article-title":"CREB family transcription factors are major mediators of BDNF transcriptional autoregulation in cortical neurons","volume":"40","author":"Esvald","year":"2022","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109219_bib21","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41380-018-0256-5","article-title":"Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)","volume":"25","author":"Fava","year":"2020","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1176\/appi.ajp.2020.20050596","article-title":"A randomized controlled trial of repeated ketamine administration for chronic posttraumatic stress disorder","volume":"178","author":"Feder","year":"2021","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib23","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamapsychiatry.2014.62","article-title":"Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial","volume":"71","author":"Feder","year":"2014","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00213-019-05346-5","article-title":"MPTP-induced dopaminergic neurotoxicity in mouse brain is attenuated after subsequent intranasal administration of (R)-ketamine: a role of TrkB signaling","volume":"237","author":"Fujita","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109219_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1124\/jpet.116.239228","article-title":"Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine","volume":"362","author":"Fukumoto","year":"2017","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109219_bib26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1176\/appi.ajp.2017.17060647","article-title":"Ketamine for rapid reduction of suicidal thoughts in major depression: a midazolam-controlled randomized clinical trial","volume":"175","author":"Grunebaum","year":"2018","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1440-1819.2010.02113.x","article-title":"Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions","volume":"64","author":"Hashimoto","year":"2010","journal-title":"Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109219_bib28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pneurobio.2012.09.001","article-title":"Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression","volume":"100","author":"Hashimoto","year":"2013","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2022.109219_bib29","doi-asserted-by":"crossref","first-page":"72","DOI":"10.9758\/cpn.2014.12.1.72","article-title":"The R-Stereoisomer of ketamine as an alternative for ketamine for treatment-resistant major depression","volume":"12","author":"Hashimoto","year":"2014","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109219_bib30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jphs.2014.11.010","article-title":"Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication","volume":"127","author":"Hashimoto","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109219_bib31","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1080\/14728222.2016.1238899","article-title":"Ketamine's antidepressant action: beyond NMDA receptor inhibition","volume":"20","author":"Hashimoto","year":"2016","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.neuropharm.2022.109219_bib32","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1176\/appi.ajp.2016.16040411","article-title":"Detrimental side effects of repeated ketamine infusions in the brain","volume":"173","author":"Hashimoto","year":"2016","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib33","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/pcn.12902","article-title":"Rapid-acting antidepressant ketamine, its metabolites and other candidates: a historical overview and future perspective","volume":"73","author":"Hashimoto","year":"2019","journal-title":"Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109219_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113935","article-title":"Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine","volume":"177","author":"Hashimoto","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109219_bib35","doi-asserted-by":"crossref","first-page":"11200","DOI":"10.1073\/pnas.2001264117","article-title":"Are NMDA and opiood receptors involved in the antidepressant actions of ketamine?","volume":"117","author":"Hashimoto","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neuropharm.2022.109219_bib36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00406-020-01231-x","article-title":"Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor","volume":"271","author":"Hashimoto","year":"2021","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109219_bib37","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-022-01587-7","article-title":"Ketamine: anesthetic, psychotomimetic, antidepressant, or anthelmintic?","author":"Hashimoto","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00406-016-0692-7","article-title":"Reduction of dopamine D2\/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys","volume":"267","author":"Hashimoto","year":"2017","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109219_bib39","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.biopsych.2017.12.007","article-title":"What are the causes for discrepancies of antidepressant actions of (2R,6R)-hydroxynorketamine?","volume":"84","author":"Hashimoto","year":"2018","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib40","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.brainresrev.2004.02.003","article-title":"Critical role of brain-derived neurotrophic factor in mood disorders","volume":"45","author":"Hashimoto","year":"2004","journal-title":"Brain Res. Brain Res. Rev."},{"key":"10.1016\/j.neuropharm.2022.109219_bib41","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/s41380-021-01432-3","article-title":"Mechanisms of action of fluvoxamine for COVID-19: a historical review","volume":"27","author":"Hashimoto","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib42","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00406-018-0922-2","article-title":"Is (S)-norketamine an alternative antidepressant for esketamine?","volume":"269","author":"Hashimoto","year":"2019","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109219_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114892","article-title":"Mechanisms of ketamine and its metabolites as antidepressants","volume":"197","author":"Hess","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109219_bib44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hup.1106","article-title":"Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered","volume":"25","author":"Hindmarch","year":"2010","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109219_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109171","article-title":"Ketamine; history and role in anesthetic pharmacology","volume":"216","author":"Hirota","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109219_bib46","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/00000542-199901000-00023","article-title":"Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells","volume":"90","author":"Hirota","year":"1999","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2022.109219_bib47","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2835","article-title":"N,N-dimethyltryptamine and Amazonian ayahuasca plant medicine","volume":"37","author":"James","year":"2022","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109219_bib48","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/0269881120959644","article-title":"Ketamine: a tale of two enantiomers","volume":"35","author":"Jelen","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109219_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euroneuro.2022.07.004","article-title":"New antidepressants: new day or false dawn?","volume":"63","author":"Jelen","year":"2022","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2022.109219_bib50","doi-asserted-by":"crossref","first-page":"104800","DOI":"10.1016\/j.neubiorev.2022.104800","article-title":"The opioid system in depression","volume":"140","author":"Jelen","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2022.109219_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp1903305","article-title":"Esketamine for treatment-resistant depression - first FDA-approved antidepressant in a new class","volume":"381","author":"Kim","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2022.109219_bib52","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1017\/S0033291716000064","article-title":"Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories","volume":"46","author":"Kishimoto","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2022.109219_bib53","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.neuron.2019.02.005","article-title":"Ketamine: a paradigm shift for depression research and treatment","volume":"101","author":"Krystal","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109219_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2019.02.001","article-title":"Antiepileptic therapy approaches in KCNQ2 related epilepsy: a systematic review","volume":"63","author":"Kuersten","year":"2020","journal-title":"Eur. J. Med. Genet."},{"key":"10.1016\/j.neuropharm.2022.109219_bib55","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00406-020-01110-5","article-title":"Intravenous arketamine for treatment-resistant depression: open-label pilot study","volume":"271","author":"Leal","year":"2021","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109219_bib56","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1146\/annurev.immunol.24.021605.090737","article-title":"Transforming growth factor-beta regulation of immune system","volume":"24","author":"Li","year":"2006","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.neuropharm.2022.109219_bib57","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2022.109219_bib58","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1016\/j.neuron.2022.05.001","article-title":"Ketamine exerts its sustained antidepressant effects via cell-type-specific regulation of Kcnq2","volume":"110","author":"Lopez","year":"2022","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109219_bib59","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.neuron.2022.05.027","article-title":"The role of hippocampal KCNQ2 channel in antidepressant actions of ketamine","volume":"110","author":"Ma","year":"2022","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109219_bib60","first-page":"27","article-title":"Nuclear factor of activated T cells 4 in the prefrontal cortex is required for prophylactic actions of (R)-ketamine. Transl","volume":"12","author":"Ma","year":"2022","journal-title":"Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109219_bib61","article-title":"Esketamine is approved in Europe for treating resistant major depressive disorder","volume":"367","author":"Mahase","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.neuropharm.2022.109219_bib62","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/appi.ajp.2020.20060864","article-title":"Improving suicide prevention through evidence-based strategies: a systematic review","volume":"178","author":"Mann","year":"2021","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib63","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng882","article-title":"Disruption of CREB function in brain leads to neurodegeneration","volume":"31","author":"Mantamadiotis","year":"2002","journal-title":"Nat. Genet."},{"key":"10.1016\/j.neuropharm.2022.109219_bib64","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1126\/science.1090842","article-title":"DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation","volume":"302","author":"Martinowich","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2022.109219_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/syn.22126","article-title":"(R)- and (S)-ketamine induce differential fMRI responses in conscious rats","volume":"73","author":"Masaki","year":"2019","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2022.109219_bib66","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jad.2022.06.036","article-title":"Mapping consent practices for outpatient psychiatric use of ketamine","volume":"312","author":"Mathai","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109219_bib67","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0304-3959(94)00170-J","article-title":"Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain","volume":"61","author":"Mathisen","year":"1995","journal-title":"Pain"},{"key":"10.1016\/j.neuropharm.2022.109219_bib68","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41573-022-00421-7","article-title":"The promises and perils of psychedelic pharmacology for psychiatry","volume":"21","author":"McClure-Begley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2022.109219_bib69","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-022-01652-1","article-title":"Blood-based biomarkers of antidepressant response to ketamine and esketamine: a systematic review and meta-analysis","author":"Medeiros","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib70","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/nn.3469","article-title":"M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination","volume":"16","author":"Miron","year":"2013","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109219_bib71","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1017\/S0033291715001506","article-title":"Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial","volume":"45","author":"Murrough","year":"2015","journal-title":"Psychol. Med."},{"key":"10.1016\/j.neuropharm.2022.109219_bib72","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0896-6273(02)00653-0","article-title":"Neurobiology of depression","volume":"34","author":"Nestler","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109219_bib73","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1176\/appi.ajp.2015.15040465","article-title":"Biomarkers APACoRTFoN, Treatments, 2015. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression","volume":"172","author":"Newport","year":"2015","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib74","doi-asserted-by":"crossref","first-page":"7969","DOI":"10.1038\/ncomms8969","article-title":"DNA\/RNA heteroduplex oligonucleotide for highly efficient gene silencing","volume":"6","author":"Nishina","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuropharm.2022.109219_bib75","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1176\/appi.ajp.21111086","article-title":"An update on community ketamine practices","volume":"179","author":"O'Brien","year":"2022","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib76","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-16060-7","article-title":"Comparison of (R)-ketamine and lanicemine on depression-like phenotype and abnormal composition of gut microbiota in a social defeat stress model","volume":"7","author":"Qu","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.109219_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113633","article-title":"The effectiveness of (R)-ketamine and its mechanism of action differ from those of (S)-ketamine in a chronic ,unpredictable mild stress model of depression in C57BL\/6J mice","volume":"418","author":"Rafalo-Ulinska","year":"2022","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2022.109219_bib78","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.euroneuro.2011.08.002","article-title":"Evaluation of sigma (\u03c3) receptors in the antidepressant-like effects of ketamine in vitro and in vivo","volume":"22","author":"Robson","year":"2012","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2022.109219_bib79","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.neubiorev.2021.10.037","article-title":"Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders","volume":"132","author":"Sa\u0142aciak","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2022.109219_bib80","doi-asserted-by":"crossref","first-page":"a022236","DOI":"10.1101\/cshperspect.a022236","article-title":"Regulation of the immune response by TGF-\u03b2: from conception to autoimmunity and infection","volume":"9","author":"Sanjabi","year":"2017","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.neuropharm.2022.109219_bib81","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2022.109219_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.114963","article-title":"Is (R)-ketamine a potential therapeutic agent for treatment-resistant depression with less detrimental side effects? A review of molecular mechanisms underlying ketamine and its enantiomers","volume":"198","author":"Scotton","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109219_bib83","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1159\/000515495","article-title":"Flexible stoichiometry: implications for KCNQ2- and KCNQ3-associated neurodevelopmental disorders","volume":"43","author":"Springer","year":"2021","journal-title":"Dev. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109219_bib84","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1038\/npp.2017.94","article-title":"Dose-related effects of adjunctive ketamine in Taiwanese patients with treatment-resistant depression","volume":"42","author":"Su","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109219_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1471-4159.2001.00054.x","article-title":"The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory","volume":"76","author":"Sweatt","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2022.109219_bib86","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jad.2020.03.040","article-title":"Risk of psychosis after repeated intermittent administration of (S)-ketamine, but not (R)-ketamine, in mice","volume":"269","author":"Tan","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.neuropharm.2022.109219_bib87","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pbb.2018.07.003","article-title":"Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R,S)-ketamine and (S)-ketamine, but not (R)-ketamine","volume":"172","author":"Tian","year":"2018","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109219_bib88","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S2215-0366(19)30394-3","article-title":"Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval","volume":"6","author":"Turner","year":"2019","journal-title":"Lancet Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib89","doi-asserted-by":"crossref","DOI":"10.1038\/s41380-022-01712-6","article-title":"Blood miR-144-3p: a novel diagnostic and therapeutic tool for depression","author":"van der Zee","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib90","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0924-977X(96)00042-9","article-title":"Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)","volume":"7","author":"Vollenweider","year":"1997","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2022.109219_bib91","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.3390\/ijms21197088","article-title":"Chaperone sigma1R and antidepressant effect","volume":"21","author":"Voronin","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109219_bib92","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.neuron.2005.05.005","article-title":"Mu-opioid receptor and CREB activation are required for nicotine reward","volume":"46","author":"Walters","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109219_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109139","article-title":"Effects of (R)-ketamine on reduced bone mineral density in ovariectomized mice: a role of gut microbiota","volume":"213","author":"Wan","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2022.109219_bib94","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1007\/s12035-019-1524-3","article-title":"The ERK pathway: molecular mechanisms and treatment of depression","volume":"56","author":"Wang","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2022.109219_bib95","first-page":"4831","article-title":"Shuyu capsules relieve liver-qi depression by regulating ERK-CREB-BDNF signal pathway in central nervous system of rat","volume":"14","author":"Wang","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.neuropharm.2022.109219_bib96","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.brainresbull.2021.10.013","article-title":"(R)-ketamine ameliorates the progression of experimental autoimmune encephalomyelitis in mice","volume":"177","author":"Wang","year":"2021","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2022.109219_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105635","article-title":"(R)-ketamine ameliorates demyelination and facilitates remyelination in cuprizone-treated mice: a role of gut-microbiota-brain axis","volume":"165","author":"Wang","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2022.109219_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104762","article-title":"(R)-ketamine as prophylactic and therapeutic drug for neurological disorders: beyond depression","volume":"139","author":"Wang","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2022.109219_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172870","article-title":"A historical review of antidepressant effects of ketamine and its enantiomers","volume":"190","author":"Wei","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109219_bib100","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.euroneuro.2021.04.010","article-title":"Intranasal administration of transforming growth factor-\u03b21 elicits rapid-acting antidepressant-like effects in a chronic social defeat stress model: a role of TrkB signaling","volume":"50","author":"Wei","year":"2021","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.neuropharm.2022.109219_bib101","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41380-021-01121-1","article-title":"Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor","volume":"27","author":"Wei","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib102","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.brainresbull.2022.02.008","article-title":"Brain - spleen axis in health and diseases: a review and future perspective","volume":"182","author":"Wei","year":"2022","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2022.109219_bib103","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/bja\/57.2.197","article-title":"Comparative pharmacology of the ketamine isomers. Studies in volunteers","volume":"57","author":"White","year":"1985","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2022.109219_bib104","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data meta-analysis","volume":"175","author":"Wilkinson","year":"2018","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib105","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1176\/appi.ajp.2018.18020138","article-title":"Attenuation of antidepressant effects of ketamine by opioid receptor antagonism","volume":"175","author":"Williams","year":"2018","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib106","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/s41380-019-0503-4","article-title":"Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism","volume":"24","author":"Williams","year":"2019","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib107","doi-asserted-by":"crossref","first-page":"pyw080","DOI":"10.1093\/ijnp\/pyw080","article-title":"Antidepressant effects of (+)-MK-801 and (-)-MK-801 in the social defeat stress model","volume":"19","author":"Yang","year":"2016","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109219_bib108","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.psychres.2016.03.034","article-title":"Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine","volume":"239","author":"Yang","year":"2016","journal-title":"Psychiatr. Res."},{"key":"10.1016\/j.neuropharm.2022.109219_bib109","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.biopsych.2018.05.007","article-title":"AMPA receptor activation-independent antidepressant actions of ketamine metabolite (S)-norketamine","volume":"84","author":"Yang","year":"2018","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib110","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/s41398-017-0031-4","article-title":"Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model","volume":"7","author":"Yang","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109219_bib111","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.biopsych.2017.05.016","article-title":"Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model","volume":"83","author":"Yang","year":"2018","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib112","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.136","article-title":"R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects","volume":"5","author":"Yang","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109219_bib113","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41398-019-0624-1","article-title":"Molecular and cellular mechanisms underlying the antidepressant effects of ketamine enantiomers and its metabolites","volume":"9","author":"Yang","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109219_bib114","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1038\/s41380-021-01377-7","article-title":"Microglial ERK-NRBP1-CREB-BDNF signaling in sustained antidepressant actions of (R)-ketamine","volume":"27","author":"Yao","year":"2022","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib115","doi-asserted-by":"crossref","first-page":"7321","DOI":"10.1093\/nar\/gkz492","article-title":"Highly efficient silencing of microRNA by heteroduplex oligonucleotides","volume":"47","author":"Yoshioka","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuropharm.2022.109219_bib116","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature17998","article-title":"NMDAR inhibition-independent antidepressant actions of ketamine metabolites","volume":"533","author":"Zanos","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2022.109219_bib117","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.117.015198","article-title":"Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms","volume":"73","author":"Zanos","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2022.109219_bib118","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119882","article-title":"(R)-Ketamine ameliorates lethal inflammatory responses and multi-organ injury in mice induced by cecum ligation and puncture","volume":"284","author":"Zhang","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2022.109219_bib120","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1007\/s00213-021-05889-6","article-title":"(R)-Ketamine attenuates LPS-induced endotoxin-derived delirium through inhibition of neuroinflammation","volume":"238","author":"Zhang","year":"2021","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109219_bib121","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.pbb.2013.11.033","article-title":"R(-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine","volume":"116","author":"Zhang","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2022.109219_bib122","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/14737175.2019.1554434","article-title":"An update on ketamine and its two enantiomers as rapid-acting antidepressants","volume":"19","author":"Zhang","year":"2019","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuropharm.2022.109219_bib123","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.biopsych.2018.11.006","article-title":"Lack of opioid system in the antidepressant actions of ketamine","volume":"85","author":"Zhang","year":"2019","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109219_bib124","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00406-019-01092-z","article-title":"Splenic NKG2D confers resilience versus susceptibility in mice after chronic social defeat stress: beneficial effects of (R)-ketamine","volume":"271","author":"Zhang","year":"2021","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109219_bib125","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41398-020-0733-x","article-title":"Essential role of microglial transforming growth factor-\u03b21 in antidepressant actions of (R)-ketamine and the novel antidepressant TGF-\u03b21","volume":"10","author":"Zhang","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109219_bib126","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2174\/1570159X14666160119094646","article-title":"Brain-derived neurotrophic factor (BDNF)-trkB signaling in inflammation-related depression and potential therapeutic targets","volume":"14","author":"Zhang","year":"2016","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.neuropharm.2022.109219_bib127","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.3390\/ijerph17134710","article-title":"Assessment of ketamine and its enantiomers in an organophosphate-based rat model for features of Gulf War illness","volume":"17","author":"Zhu","year":"2020","journal-title":"Int. J. Environ. Res. Publ. Health"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822002787?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822002787?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:19:00Z","timestamp":1758439140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822002787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":127,"alternative-id":["S0028390822002787"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109219","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arketamine, a new rapid-acting antidepressant: A historical review and future directions","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109219","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109219"}}